HFSA Annual Scientific Meeting 2022

Join us for this year's Presidential Plenary and our opening keynote address:

Creation and Translation: Making Discoveries and Bringing Them to the Bedside, Michael Bristow, MD, PhD, Professor of Medicine (Cardiology) at the University of Colorado Anschutz Medical Campus, and Director of the Section of Pharmacogenomics in the University of Colorado Cardiovascular Institute

Setting the Agenda: Funding Strategies to Maximize Innovation, Gary Gibbons, MD, Director of the National Heart, Lung, and Blood Institute (NHLBI)

Discussion: Drs Bristow and Gibbons will be joined by additional panelists in a discussion on how to enhance and sustain innovation in the field.

Also featured during the Opening Plenary session:

• HFSA President’s Address
  • Mark Drazner, MD, MSc, FHFSA, HFSA President
  • John Teerlink, MD, HFSA President-Elect and Director of Heart Failure and of the Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center
• HFSA Award announcements

Late Breaking Clinical Trials Session I

• Effect of Empagliflozin on Clinical Events in Patients Hospitalized for Acute Heart Failure: Results from EMPULSE
• Dapagliflozin in Heart Failure with Improved Ejection Fraction
• Voice Analysis-Based Telemonitoring Predicts Worsening Heart Failure Events with Markedly Greater Sensitivity than Daily Weight Monitoring
• Oral Sodium to Preserve Renal Efficiency in Acute Heart Failure (OSPREY-AHF): A Single-Center, Double-Blind, Randomized, Placebo-Controlled Trial
• Effect of Sacubitril/Valsartan on Mitral Regurgitation in Heart Failure with Reduced Ejection Fraction. The PROVE-HF Study
• Blood Pressure, Dapagliflozin, And Cardiovascular Outcomes in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Deliver

Learn more about Late Breaking Clinical Trials Session II >>

The session will explore the scientific advances that laid the groundwork for this innovative surgery to occur, clinical translation of xenotransplant, detailed case review of the first successful human heart xenotransplant, and broad discussions of the future for xenotransplantation including clinical potential, challenges, ethical considerations, and other concepts clinicians and researchers need to know for future heart failure care.

The Science and Background Enabling Xenotransplantation, Muhammad M. Mohiuddin, MD, Professor of Surgery and Scientific/Program Director, Cardiac Xenotransplantation Program at UMSOM

The First Successful Human Heart Xenotransplant, Bartley P. Griffith, MD, Thomas E. and Alice Marie Hales Distinguished Professor in Transplant Surgery and Clinical Director, Cardiac Xenotransplantation Program at UMSOM

Echocardiogram Findings, Susie N. Hong-Zohlman, MD, MSc, Medical Director of the Echocardiography Laboratories at the University of Maryland Medical Center Downtown and Midtown Campuses

Patient Selection, Susan Joseph, MD, Cardiologist, Associate Professor of Medicine at UMSOM and Section Chief, Advanced Heart Failure and Transplant Cardiology at UMMC

Future of Cardiac Xenotransplant: Ethical Considerations, Savitri Fedson, MD, MA, Associate Professor, Center for Medical Ethics and Health Policy, Baylor College of Medicine

Panel Discussion: All

Moderators 

• Daniel Garry, MD, PhD, ASM Program Co-Chair
• Cheryl Westlake, PhD, RN, ASM Program Co-Chair